


## (RS)-(Tetrazol-5-yl)glycine

Cat. No.:	HY-100839
CAS No.:	138199-51-6
Molecular Formula:	C <sub>5</sub> H <sub>5</sub> N <sub>5</sub> O <sub>2</sub>
Molecular Weight:	143.1
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist <sup>[1]</sup> . (RS)-(Tetrazol-5-yl)glycine has EC <sub>50</sub> s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively <sup>[2]</sup> . (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice <sup>[3]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	NMDA Receptor								
<b>In Vitro</b>	(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is an agonist of N-methyl-D-aspartate (NMDA) subtype of excitatory amino acid receptor. (RS)-(Tetrazol-5-yl)glycine displaces NMDA receptor binding to rat brain membranes as measured using [ <sup>3</sup> H]CGS19755 (IC <sub>50</sub> =98 nM) and [ <sup>3</sup> H]glutamate (IC <sub>50</sub> =36 nM) as ligands <sup>[1]</sup> . (RS)-(Tetrazol-5-yl)glycine does not appreciably inhibit the binding of D,L-alpha-[5-methyl-3H] amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), [ <sup>3</sup> H]kainate, or [ <sup>3</sup> H]glycine (IC <sub>50</sub> >30 μM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	(RS)-(Tetrazol-5-yl)glycine can be used in animal modeling to construct epilepsy models.  (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine; 1.25, 1.5 mg/kg; IP) induces seizure responses and Fos in the NR1+/+ and NR1-/- mice <sup>[3]</sup> . (RS)-(Tetrazol-5-yl)glycine is a highly potent convulsant when given to neonatal rats (ED <sub>50</sub> =0.071 mg/kg; i.p.) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6 mice<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1.25, 1.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP</td> </tr> <tr> <td>Result:</td> <td>Induced seizure responses and Fos.</td> </tr> </table>	Animal Model:	C57BL/6 mice <sup>[3]</sup>	Dosage:	1.25, 1.5 mg/kg	Administration:	IP	Result:	Induced seizure responses and Fos.
Animal Model:	C57BL/6 mice <sup>[3]</sup>								
Dosage:	1.25, 1.5 mg/kg								
Administration:	IP								
Result:	Induced seizure responses and Fos.								

### REFERENCES

[1]. Schoepp DD, et al. D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonist. Eur J Pharmacol. 1991 Oct 15;203(2):237-43.

---

[2]. Vance KM, et al. Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat Commun. 2011;2:294.

[3]. Duncan GE, et al. Seizure responses and induction of Fos by the NMDA agonist (tetrazol-5-yl)glycine in a genetic model of NMDA receptor hypofunction. Brain Res. 2008 Jul 24;1221:41-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA